Objective: To investigate the effect of cilostazol on the expression of CD(54), CD(106), CD(62P) in kidney, aorta, surface of platelet, and mononuclear cell of blood in STZ-induced diabetic rats.
Methods: Rats were randomly divided into four groups: normal control group (n = 8), diabetes control group (n = 8), insulin group (n = 7 subcutaneous injection of insulin, 1 approximately 4 U * d(-1)), and cilostazol group (n = 7, gastric infusion of cilostazol, 18 mg * kg(-1) * d(-1)). Sciatic nerve conductive velocity and level of CD(54)/CD(62p) on the surface of mononuclear cell/platelet were examined by flow cytometry. Immunohistochemistry was used to examine the expression of CD(54) and/or CD(106) in kidney and aorta.
Results: The sciatic nerve conductive velocity was 20.3 +/- 2.2 m * s(-1) and 28.9 +/- 7.9 m * s(-1) in diabetic rats and cilostazol group respectively (P < 0.05). The mononuclear cell surface expression of CDa-a(c)54 was 69.1 +/- 14.9% and 25.9 +/- 8.6% in diabetic group and cilostazol group respectively (P < 0.05). The expression of CD(54)/CD(106) in kidney and aorta was decreased. The expression of CD(62p) on the surface of platelets was 40.4 +/- 8.7% in diabetic group and 28.5 +/- 3.7% in cilostazol group (P > 0.05).
Conclusion: Cilostazol treatment delays the development of diabetic pathological change in kidney, aorta and sciatic nerve and decreases the expression of CD(54) and CD(106).